Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EXACT SCIENCES CORPORATION

(EXAS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Exact Sciences Corp. Shares Data from Modeling Analyses that Demonstrate Cologuard

10/25/2021 | 05:33pm EST

Exact Sciences Corp. shared data from modeling analyses that demonstrate Cologuard (mt-sDNA), with its included patient navigation system, provides a greater reduction in incidence and mortality from colorectal cancer (CRC) compared to annual fecal immunochemical test (FIT), when it included outreach, with or without a mailed annual FIT, using real world adherence rates in a simulated Medicaid population. Cologuard remained cost-effective in all the real-world adherence scenarios modeled. The modeling analyses were consistent with the CISNET Colorectal Working Group models when using 100% adherence rates. The Exact Sciences Laboratories Patient Navigation Program features on-demand phone support, reminder phone calls, texts and emails at no additional cost with each Cologuard test ordered. These new data, generated from the CRC-AIM microsimulation model, will be presented in an ACG Presidential Award-winning poster titled, "Cost-Effectiveness of Stool-Based Colorectal Cancer Screening Using Reported Real-World Adherence Rates in a Medicare Population.


© S&P Capital IQ 2021
All news about EXACT SCIENCES CORPORATION
11/23Exact Sciences Says New Data in Clinically Low-Risk Prostate Cancer Patients Backs Use ..
MT
11/23New 20-Year Data Published in Urologic Oncology Validates Adverse Pathology as Predicto..
PR
11/23Exact Sciences Corporation Announces Publication of Results Underscoring the Importance..
CI
11/18Exact Sciences Partners With Jefferson Health on Multi-Cancer Earlier Detection Test Re..
MT
11/18Exact Sciences and Jefferson Health Commence Collaboration on Multi-Cancer Earlier Dete..
PR
11/18Exact Sciences and Jefferson Health Commence Collaboration on Multi-Cancer Earlier Dete..
CI
11/04NORTH AMERICAN MORNING BRIEFING : Stocks Futures -3-
DJ
11/03INSIDER SELL : Exact Sciences
MT
11/03BTIG Adjusts Exact Sciences' Price Target to $120 From $145, Reiterates Buy Rating
MT
11/03Wells Fargo Adjusts Price Target on Exact Sciences to $95 From $120, Maintains Equal-We..
MT
More news
Analyst Recommendations on EXACT SCIENCES CORPORATION
More recommendations
Financials (USD)
Sales 2021 1 735 M - -
Net income 2021 -520 M - -
Net Debt 2021 1 330 M - -
P/E ratio 2021 -28,5x
Yield 2021 -
Capitalization 14 918 M 14 918 M -
EV / Sales 2021 9,36x
EV / Sales 2022 8,21x
Nbr of Employees 4 900
Free-Float 99,3%
Chart EXACT SCIENCES CORPORATION
Duration : Period :
Exact Sciences Corporation Technical Analysis Chart | EXAS | US30063P1057 | MarketScreener
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 86,57 $
Average target price 129,35 $
Spread / Average Target 49,4%
EPS Revisions
Managers and Directors
Kevin T. Conroy Chairman, President & Chief Executive Officer
Jeffrey Thomas Elliott Executive VP, Chief Operating & Financial Officer
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Sandra Statz Senior VP-Clinical & Regulatory Affairs
Gary Frings Chief Information Officer
Sector and Competitors
1st jan.Capi. (M$)
EXACT SCIENCES CORPORATION-34.66%14 918
GUARDANT HEALTH, INC.-19.38%10 562
BGI GENOMICS CO., LTD.-27.94%5 945
INVITAE CORPORATION-59.01%3 880
ADAPTIVE BIOTECHNOLOGIES CORPORATION-54.93%3 761
SEEGENE, INC.-22.28%3 254